Healthcare stocks managed a modest gain on Tuesday, but the sector's biotech corner lagged behind, underscoring how different parts of the healthcare universe can move in opposite directions. The Health Care Select Sector SPDR Fund (XLV) added about 0.2%, while the iShares Biotechnology ETF slipped 0.8%. The divergence was driven by a mix of earnings disappointments and deal news that hit individual companies hard.
What's behind the split?
The performance gap between XLV and biotech funds is a reminder that "healthcare" is not a single, uniform category. XLV and similar broad sector funds are market-cap weighted, meaning their daily moves are dominated by the largest, most established companies in the sector—pharmaceutical giants, managed-care insurers, and medical-device makers. These firms tend to generate steady cash flows and are often seen as defensive holdings, especially when investors are feeling cautious about the broader economy.
Biotech-focused funds, by contrast, are packed with smaller companies whose valuations hinge on drug-development milestones, clinical trial results, and access to funding. That makes them far more volatile and sensitive to company-specific news. When a biotech company reports disappointing earnings or faces competitive threats, its stock can swing dramatically, dragging down the entire fund.
Hims & Hers: A sharp drop after a Q3 loss
Telehealth company Hims & Hers was a standout decliner, sliding more than 17% after reporting a third-quarter loss. The company posted a loss of $0.14 per diluted share, compared with earnings of $0.06 per share in the same period a year earlier. The sharp reversal highlights the challenges facing direct-to-consumer health companies, which often face high marketing costs and regulatory scrutiny.
For investors, the move is a reminder that even fast-growing healthcare names can be volatile when quarterly results miss expectations. Hims & Hers had been a high-flyer in the telehealth space, but its latest report suggests that profitability is not yet on a steady path.
Other movers: ADC Therapeutics and AstraZeneca
The biotech ETF's weaker showing also came alongside mixed single-stock reactions. Cancer-drug developer ADC Therapeutics fell nearly 10% even after RBC Capital Markets, an investment bank, said a recent restructuring had improved its finances. The bank described the company's Lotis-7 data as encouraging but noted that competition could cloud its revenue outlook. That caution weighed on the stock, showing that even positive commentary may not be enough to offset broader concerns about market share.
Meanwhile, drugmaker AstraZeneca dipped about 1.2% after announcing it would acquire Omniose, an early-stage biotech. The deal is part of AstraZeneca's strategy to bolster its pipeline, but investors often react cautiously to acquisitions, especially when the target is pre-revenue and the price tag is undisclosed.
What it means for investors
The day's action is a useful illustration of how healthcare exposure can behave differently depending on the vehicle you choose. Broad healthcare funds like XLV tend to act more like a defensive equity slice, offering stability and dividends. Biotech ETFs, on the other hand, are more like a collection of high-uncertainty stories, where trial readouts, competition, and cash runway can outweigh the broader market's mood.
That's why XLV can inch higher even as the iShares Biotechnology ETF falls and a single smaller stock gets hit after a disappointing quarter. If a headline says "healthcare is up," it often means the mega-caps that dominate broad ETFs held their ground—not that every corner of the sector was strong.
For everyday investors, the takeaway is about risk drivers. If you own a broad healthcare fund, you're likely getting exposure to stable, cash-generating businesses. If you own a biotech fund, you're signing up for more volatility and company-specific risk. Performance gaps between XLV and biotech funds can open quickly, especially around earnings season, clinical-data updates, or M&A announcements.
As always, it's important to understand what you own and how it fits into your overall portfolio. Healthcare can be a defensive anchor, but biotech is a different beast entirely.
